Trial Profile
A Phase 1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs EOC 317 (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Gastric cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors EOC Pharma
- 10 Sep 2019 Planned primary completion date changed from 29 May 2019 to 29 Feb 2020.
- 19 Jul 2018 New trial record